Market Overview

UPDATE: Stifel Nicolaus Raises PT to $20 on Sabra Health Care REIT on Enhanced Acquisition Visibility

Related SBRA
Benzinga's Top Downgrades
Benzinga's Top Upgrades
FBR spots value in two roughed-up REITs (Seeking Alpha)

Stifel Nicolaus reiterated its Buy rating on Sabra Health Care REIT (NASDAQ: SBRA) and raised its price target from $17 to $20.

Stifel Nicolaus commented, "We are raising our price target for Sabra Health Care REIT from $17 to $20 as we expect accretive investment activity to ramp up given its targets' success in restoring margins affected by last year's Medicare rate cuts. We believe that the operators of skilled nursing facilities (SNFs) have mitigated last October's 11.1% Medicare rate cut and are now in a position to monetize real estate assets. An uptick in accretive acquisitions over the pace of the first half of the year would enable Sabra to sustain above-average growth."

Sabra Health Care REIT closed at $17.89 on Friday.

Latest Ratings for SBRA

Oct 2015FBR CapitalReinstatesOutperform
Sep 2015RBC CapitalDowngradesOutperformSector Perform
Sep 2015Mizuho SecuritiesMaintainsBuy

View More Analyst Ratings for SBRA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SBRA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters